11 completed, 9 recruiting, 3 terminated, 2 not yet recruiting. 30 Phase 2, 7 Phase 1, 5 Phase 3.
Follow sarilumab: new trials by email Literature Review of sarilumab trials Research Report on sarilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 192 | 2027-06-28 | 2026-09-30 |
| Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events Sarilumab, ICI Therapy - Any Advanced Solid Tumors | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 41 | 2026-12-01 | 2026-10-28 |
| Phase 1b/2 Study of IV Sarilumab in Adult With RA Sarilumab, SAR153191 SC, Sarilumab, SAR153191 IV - Rheumatoid Arthritis | Phase 1 / Phase 2 | Recruiting | Sanofi | 140 | 2026-07-02 | 2026-10-13 |
| A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Ubamatamab, Marlotamig, Sarilumab - Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 300 | 2026-03-18 | 2026-10-22 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Ubamatamab, Bevacizumab, Cemiplimab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 297 | 2025-05-28 | 2026-09-14 |
| Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab - Melanoma, Unresectable Melanoma | Phase 2 | Recruiting | NYU Langone Health | 105 | 2023-02-02 | 2026-10-28 |
| Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab - Skin Inflammation, Allergic Contact Dermatitis | Phase 2 / Phase 3 | Active not recruiting | Wei-Che Ko | 45 | 2022-11-15 | 2026-06-09 |
| Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis Tocilizumab, Sarilumab - Arthritis, Rheumatoid, Interaction | Phase 1 / Phase 2 | Terminated | University of Southern Denmark | 3 | 2021-05-25 | 2023-01-25 |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab REGN5668, Cemiplimab, Ubamatamab - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 612 | 2020-12-08 | 2026-09-24 |
| A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine - Breast, Metastatic | Phase 1 / Phase 2 | Recruiting | University of Southern California | 65 | 2020-09-26 | 2026-03-10 |
| Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19 Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo - COVID, COVID-19 | Phase 2 | Withdrawn | BayCare Health System | 2020-05-07 | 2025-09-29 | |
| Clinical Trial of Sarilumab in Adults With COVID-19 Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA], Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA], Best available treatment - SARS-CoV 2, SARS | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 120 | 2020-04-28 | 2021-07-07 |
| Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19 Sarilumab - COVID-19 Drug Treatment | Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 60 | 2020-04-22 | 2020-12-16 |
| Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID) Sarilumab, Standar of care - Covid-19 | Phase 2 | Completed | Maria del Rosario Garcia de Vicuña Pinedo | 30 | 2020-04-13 | 2021-02-11 |
| Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO Sarilumab, Azithromycin, Hydroxychloroquine - COVID19, SARS-CoV-2 Infection | Phase 2 / Phase 3 | Suspended | Assistance Publique - Hôpitaux de Paris | 27 | 2020-04-11 | 2020-05-06 |
| Sarilumab for Patients With Moderate COVID-19 Disease SARILUMAB - COVID | Phase 2 | Completed | Westyn Branch-Elliman | 50 | 2020-04-10 | 2023-12-06 |
| Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI Sarilumab - Corona Virus Infection | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 239 | 2020-03-27 | 2025-06-12 |
| Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 Sarilumab, Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | Regeneron Pharmaceuticals | 1912 | 2020-03-18 | 2021-09-23 |
| Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis Sarilumab, Placebo - Sarcoidosis | Phase 2 | Completed | Stanford University | 16 | 2019-09-03 | 2023-10-05 |
| Study to Assess Sarilumab in Halting Progression of Morphea Sarilumab - Morphea, Plaque Form | Phase 1 / Phase 2 | Withdrawn | Massachusetts General Hospital | 2019-09-01 | 2021-09-08 |
Showing 20 of 30. Sign in to see all of them.
Arthritis, Rheumatoid (4) · COVID-19 (4) · Coronavirus Infections (4) · Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3) · Arthritis, Juvenile (2) · Endometrial Neoplasms (2) · Neoplasms (2) · Spondylitis, Ankylosing (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Dermatitis (1) · Dermatitis, Allergic Contact (1) · Hemangiosarcoma (1) · Lung Neoplasms (1)
Sanofi (8) · Regeneron Pharmaceuticals (6) · Assistance Publique - Hôpitaux de Paris (2) · BayCare Health System (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Maimónides Biomedical Research Institute of Córdoba (1) · Maria del Rosario Garcia de Vicuña Pinedo (1) · Massachusetts General Hospital (1) · NYU Langone Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · QuantumLeap Healthcare Collaborative (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Stanford University (1) · University of Southern California (1) · University of Southern Denmark (1)
United States (22) · Spain (12) · France (9) · Canada (6) · Czechia (6) · Belgium (5) · Italy (5) · Netherlands (5) · Australia (4) · Germany (4) · Hungary (4) · Mexico (4) · Poland (4) · Turkey (Türkiye) (4) · Argentina (3)
Aliyah Pabani, MD (1) · Anastasia Martynova, MD (1) · Ann-Cathrine Dunvald, MD (1) · Danielle Mauck, BA (1) · Hirsh D Komarow, M.D. (1) · Janice Mehnert, MD (1) · Javier J Zulueta, MD (1) · Laura Esserman, MD, MBA (1) · Mark C Genovese, MD, Professor of Medicine (1) · Matthew Baker, MD (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 24297381, PMID 24550171, PMID 25733246, PMID 27406346, PMID 27406347, PMID 27716324, PMID 28851423, PMID 31004324, PMID 31452928, PMID 32031889, PMID 32053137, PMID 32343882, PMID 32450725, PMID 32522251, PMID 32701140, PMID 32907617, PMID 32907638, PMID 33191263, PMID 34496013, PMID 34519964, PMID 34529000, PMID 34741021, PMID 34812424, PMID 34902262, PMID 35115337, PMID 35213547, PMID 35219277, PMID 35280907, PMID 35623341, PMID 35993306, PMID 36008838, PMID 36069821, PMID 36413080, PMID 36456573, PMID 36494054, PMID 37029329, PMID 37325931, PMID 37471590, PMID 37505107, PMID 37831074, PMID 38077399, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671
2009 (2), 2015 (1), 2019 (1), R01CA238387 (1)